AR129312A1 - Composiciones y métodos para inhibir la expresión de snca - Google Patents
Composiciones y métodos para inhibir la expresión de sncaInfo
- Publication number
- AR129312A1 AR129312A1 ARP230101181A ARP230101181A AR129312A1 AR 129312 A1 AR129312 A1 AR 129312A1 AR P230101181 A ARP230101181 A AR P230101181A AR P230101181 A ARP230101181 A AR P230101181A AR 129312 A1 AR129312 A1 AR 129312A1
- Authority
- AR
- Argentina
- Prior art keywords
- region
- antisense strand
- gene expression
- complementarity
- snca
- Prior art date
Links
- 230000014509 gene expression Effects 0.000 title abstract 7
- 102100026882 Alpha-synuclein Human genes 0.000 title abstract 3
- 101000834898 Homo sapiens Alpha-synuclein Proteins 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 2
- 230000002401 inhibitory effect Effects 0.000 title 1
- 108091034117 Oligonucleotide Proteins 0.000 abstract 9
- 230000000692 anti-sense effect Effects 0.000 abstract 8
- 101150110423 SNCA gene Proteins 0.000 abstract 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 6
- 108091030071 RNAI Proteins 0.000 abstract 5
- 230000009368 gene silencing by RNA Effects 0.000 abstract 5
- 239000002773 nucleotide Substances 0.000 abstract 5
- 125000003729 nucleotide group Chemical group 0.000 abstract 5
- 108091081021 Sense strand Proteins 0.000 abstract 3
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 abstract 3
- 201000010099 disease Diseases 0.000 abstract 3
- 208000035475 disorder Diseases 0.000 abstract 3
- 108020004999 messenger RNA Proteins 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 206010003694 Atrophy Diseases 0.000 abstract 1
- 206010067889 Dementia with Lewy bodies Diseases 0.000 abstract 1
- 201000002832 Lewy body dementia Diseases 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 230000037444 atrophy Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000003446 ligand Substances 0.000 abstract 1
- 150000002632 lipids Chemical group 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 230000009885 systemic effect Effects 0.000 abstract 1
- 230000008685 targeting Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/312—Phosphonates
- C12N2310/3125—Methylphosphonates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/322—2'-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3515—Lipophilic moiety, e.g. cholesterol
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
- C12N2310/3521—Methyl
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/353—Nature of the modification linked to the nucleic acid via an atom other than carbon
- C12N2310/3533—Halogen
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
- C12N2310/531—Stem-loop; Hairpin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Bakery Products And Manufacturing Methods Therefor (AREA)
- Saccharide Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
En el presente documento se proporcionan oligonucleótidos (por ejemplo, oligonucleótidos de ARNi) que inhiben la expresión génica de SNCA, incluyendo oligonucleótidos conjugados con un ligando de direccionamiento (por ejemplo, resto de GalNAC o resto lipídico). También se proporcionan composiciones que incluyen estas y sus usos, particularmente usos relacionados con el tratamiento de enfermedades, trastornos y/o afecciones asociadas con la expresión génica de SNCA. Reivindicación 1: Un oligonucleótido de ARNi para reducir la expresión génica de SNCA, donde el oligonucleótido comprende una hebra de sentido y una hebra de antisentido, en donde la hebra de sentido y la hebra de antisentido forman una región dúplex, en donde la hebra de antisentido comprende una región de complementariedad con una secuencia diana de ARNm de SNCA de una cualquiera de las SEQ ID Nº 1683 - 2066, y en donde la región de complementariedad tiene al menos 15 nucleótidos contiguos de longitud. Reivindicación 8: Un oligonucleótido de ARNi bicatenario para reducir la expresión génica de SNCA, donde el oligonucleótido comprende: (i) una hebra de antisentido de 19 - 30 nucleótidos de longitud, en donde la hebra de antisentido comprende una secuencia de nucleótidos que comprende una región de complementariedad con una secuencia diana de ARNm de SNCA, en donde la región de complementariedad se selecciona de las SEQ ID Nº 2067 - 2450 y (ii) una hebra de sentido de 19 - 50 nucleótidos de longitud que comprende una región de complementariedad con la hebra de antisentido, en donde las hebras de antisentido y sentido son hebras separadas que forman una región dúplex asimétrica que tiene un saliente de 1 - 4 nucleótidos en el extremo 3 de la hebra de antisentido. Reivindicación 111: Uso del oligonucleótido de ARNi de cualquiera de las reivindicaciones 1 a 97, o la composición farmacéutica de la reivindicación 98, en la fabricación de un medicamento para el tratamiento de una enfermedad, trastorno o afección asociada con la expresión génica de SNCA. Reivindicación 114: El uso de la reivindicación 111, el oligonucleótido de ARNi o composición farmacéutica para su uso, o adaptable para su uso, de la reivindicación 112, o el kit de la reivindicación 113, en donde la enfermedad, trastorno o afección asociada con la expresión génica de SNCA es atrofia sistémica múltiple, demencia con cuerpos de Lewy y enfermedad de Parkinson.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263364639P | 2022-05-13 | 2022-05-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR129312A1 true AR129312A1 (es) | 2024-08-14 |
Family
ID=86760635
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP230101181A AR129312A1 (es) | 2022-05-13 | 2023-05-12 | Composiciones y métodos para inhibir la expresión de snca |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20230416743A1 (es) |
| EP (1) | EP4522748A1 (es) |
| JP (1) | JP2025518507A (es) |
| KR (1) | KR20250024534A (es) |
| CN (1) | CN119630791A (es) |
| AR (1) | AR129312A1 (es) |
| AU (1) | AU2023267664A1 (es) |
| CA (1) | CA3250061A1 (es) |
| CL (2) | CL2024003390A1 (es) |
| CO (1) | CO2024015326A2 (es) |
| CR (1) | CR20240494A (es) |
| DO (1) | DOP2024000226A (es) |
| IL (1) | IL316843A (es) |
| MX (1) | MX2024013992A (es) |
| PE (1) | PE20250929A1 (es) |
| TW (1) | TW202409275A (es) |
| WO (1) | WO2023220351A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025151407A1 (en) * | 2024-01-08 | 2025-07-17 | Denali Therapeutics Inc. | Compositions and methods for modulating alpha-synuclein expression |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6469158B1 (en) | 1992-05-14 | 2002-10-22 | Ribozyme Pharmaceuticals, Incorporated | Synthesis, deprotection, analysis and purification of RNA and ribozymes |
| US5804683A (en) | 1992-05-14 | 1998-09-08 | Ribozyme Pharmaceuticals, Inc. | Deprotection of RNA with alkylamine |
| US5977343A (en) | 1992-05-14 | 1999-11-02 | Ribozyme Pharmaceuticals, Inc. | Synthesis, deprotection, analysis and purification of RNA and ribozymes |
| DK0748382T3 (da) | 1993-09-02 | 2003-02-17 | Ribozyme Pharm Inc | Enzymatisk nukleinsyre indeholdende ikke-nukleotid |
| US5889136A (en) | 1995-06-09 | 1999-03-30 | The Regents Of The University Of Colorado | Orthoester protecting groups in RNA synthesis |
| US5998203A (en) | 1996-04-16 | 1999-12-07 | Ribozyme Pharmaceuticals, Inc. | Enzymatic nucleic acids containing 5'-and/or 3'-cap structures |
| US6111086A (en) | 1998-02-27 | 2000-08-29 | Scaringe; Stephen A. | Orthoester protecting groups |
| PT1309726E (pt) | 2000-03-30 | 2010-03-08 | Whitehead Biomedical Inst | Mediadores de interferência por rna específicos de sequência de rna |
| HU230458B1 (hu) | 2000-12-01 | 2016-07-28 | Europäisches Laboratorium für Molekularbiologie (EMBL) | Az RNS interferenciát közvetítő kis RNS molekulák |
| US20050137155A1 (en) * | 2001-05-18 | 2005-06-23 | Sirna Therapeutics, Inc. | RNA interference mediated treatment of Parkinson disease using short interfering nucleic acid (siNA) |
| US20050159378A1 (en) | 2001-05-18 | 2005-07-21 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of Myc and/or Myb gene expression using short interfering nucleic acid (siNA) |
| AU2002347981A1 (en) | 2001-11-07 | 2003-05-19 | Applera Corporation | Universal nucleotides for nucleic acid analysis |
| US20070265220A1 (en) | 2004-03-15 | 2007-11-15 | City Of Hope | Methods and compositions for the specific inhibition of gene expression by double-stranded RNA |
| WO2007030167A1 (en) | 2005-09-02 | 2007-03-15 | Nastech Pharmaceutical Company Inc. | Modification of double-stranded ribonucleic acid molecules |
| WO2009079399A2 (en) * | 2007-12-14 | 2009-06-25 | Alnylam Pharmaceuticals, Inc. | Method of treating neurodegenerative disease |
| WO2010033225A2 (en) | 2008-09-22 | 2010-03-25 | Dicerna Pharmaceuticals, Inc. | Compositions and methods for the specific inhibition of gene expression by dsrna possessing modifications |
| AU2009336191B2 (en) | 2008-12-18 | 2017-08-24 | Novo Nordisk A/S | Extended dicer substrate agents and methods for the specific inhibition of gene expression |
| WO2010093788A2 (en) | 2009-02-11 | 2010-08-19 | Dicerna Pharmaceuticals, Inc. | Multiplex dicer substrate rna interference molecules having joining sequences |
| WO2011005860A2 (en) | 2009-07-07 | 2011-01-13 | Alnylam Pharmaceuticals, Inc. | 5' phosphate mimics |
| WO2011133871A2 (en) | 2010-04-22 | 2011-10-27 | Alnylam Pharmaceuticals, Inc. | 5'-end derivatives |
| HK1201555A1 (en) | 2011-10-25 | 2015-09-04 | Isis Pharmaceuticals, Inc. | Antisense modulation of gccr expression |
| JP7105065B2 (ja) | 2014-12-15 | 2022-07-22 | ダイセルナ ファーマシューティカルズ， インコーポレイテッド | リガンド修飾二本鎖核酸 |
| ES2924806T3 (es) | 2016-09-02 | 2022-10-11 | Dicerna Pharmaceuticals Inc | Análogos de 4'-fosfato y oligonucleótidos que comprenden el mismo |
| US20240084309A1 (en) * | 2020-08-04 | 2024-03-14 | Dicerna Pharmaceuticals, Inc. | Compositions and methods for inhibiting plp1 expression |
| WO2022072447A1 (en) * | 2020-10-01 | 2022-04-07 | Alnylam Pharmaceuticals, Inc. | Snca irna compositions and methods of use thereof for treating or preventing snca-associated neurodegenerative diseases |
-
2023
- 2023-05-12 WO PCT/US2023/022007 patent/WO2023220351A1/en not_active Ceased
- 2023-05-12 PE PE2024002524A patent/PE20250929A1/es unknown
- 2023-05-12 AU AU2023267664A patent/AU2023267664A1/en active Pending
- 2023-05-12 AR ARP230101181A patent/AR129312A1/es unknown
- 2023-05-12 US US18/316,561 patent/US20230416743A1/en active Pending
- 2023-05-12 CA CA3250061A patent/CA3250061A1/en active Pending
- 2023-05-12 EP EP23730271.6A patent/EP4522748A1/en active Pending
- 2023-05-12 JP JP2024567519A patent/JP2025518507A/ja active Pending
- 2023-05-12 TW TW112117718A patent/TW202409275A/zh unknown
- 2023-05-12 CN CN202380053018.5A patent/CN119630791A/zh active Pending
- 2023-05-12 CR CR20240494A patent/CR20240494A/es unknown
- 2023-05-12 KR KR1020247041461A patent/KR20250024534A/ko active Pending
- 2023-05-12 IL IL316843A patent/IL316843A/en unknown
-
2024
- 2024-11-06 CL CL2024003390A patent/CL2024003390A1/es unknown
- 2024-11-08 DO DO2024000226A patent/DOP2024000226A/es unknown
- 2024-11-12 CO CONC2024/0015326A patent/CO2024015326A2/es unknown
- 2024-11-12 MX MX2024013992A patent/MX2024013992A/es unknown
-
2025
- 2025-08-22 CL CL2025002529A patent/CL2025002529A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3250061A1 (en) | 2023-11-16 |
| TW202409275A (zh) | 2024-03-01 |
| PE20250929A1 (es) | 2025-04-02 |
| US20230416743A1 (en) | 2023-12-28 |
| AU2023267664A1 (en) | 2024-10-31 |
| MX2024013992A (es) | 2024-12-06 |
| CN119630791A (zh) | 2025-03-14 |
| CL2024003390A1 (es) | 2025-03-14 |
| DOP2024000226A (es) | 2024-12-15 |
| CL2025002529A1 (es) | 2025-11-28 |
| WO2023220351A1 (en) | 2023-11-16 |
| KR20250024534A (ko) | 2025-02-18 |
| CO2024015326A2 (es) | 2024-12-30 |
| JP2025518507A (ja) | 2025-06-17 |
| IL316843A (en) | 2025-01-01 |
| EP4522748A1 (en) | 2025-03-19 |
| CR20240494A (es) | 2025-03-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Lai et al. | Synergistic inhibition of lung cancer cell invasion, tumor growth and angiogenesis using aptamer-siRNA chimeras | |
| ES2537568T3 (es) | Nuevos fármacos para inhibición de la expresión genética | |
| CL2021002585A1 (es) | Composiciones y métodos para inhibir la expresión génica en el sistema nervioso central | |
| BRPI0811170B8 (pt) | oligonucleotídeos de rna e complexos de rna substituídos por hidroximetila | |
| MX2024005652A (es) | Agentes de acido ribonucleico (arn) de cadena doble modificados. | |
| JP2018531037A5 (es) | ||
| JP2009532392A5 (es) | ||
| AR051895A1 (es) | Metodo para disparar la interferencia de arn | |
| PE20211749A1 (es) | Oligonucleotidos antisentido que actuan sobre alfa-sinucleina, y usos de estos | |
| AR125992A1 (es) | Composiciones y métodos para inhibir la expresión del componente 1 de reducción de amidoxima mitocondrial (marc1) | |
| AR123679A1 (es) | COMPOSICIONES DE ARNi CONTRA EL GEN SNCA Y MÉTODOS DE USO DE LAS MISMAS PARA TRATAR O PREVENIR ENFERMEDADES NEURODEGENERATIVAS ASOCIADAS CON SNCA | |
| AR124713A1 (es) | Composiciones y métodos para inhibir la expresión de genes en el sistema nervioso central | |
| AR125230A1 (es) | COMPOSICIONES DE AGENTES DE ARNi CONTRA HUNTINGTINA (HTT) Y SUS MÉTODOS DE USO | |
| PE20250156A1 (es) | Composiciones y metodos para inhibir el factor b del complemento | |
| PE20250353A1 (es) | Terapeutica con arn novedosos y usos de estos | |
| AR129312A1 (es) | Composiciones y métodos para inhibir la expresión de snca | |
| BR112022002690A2 (pt) | Construtos de vesícula-aso extracelular tendo como alvo cebp/beta | |
| AR129710A1 (es) | Composiciones y métodos para inhibir la expresión de serina proteasa transmembrana 6 (tmprss6) | |
| AR124302A1 (es) | Gápmeros de oligonucleótidos de objetivo tau | |
| PE20201501A1 (es) | Oligonucleotidos antisentido que actuan sobre alfa-sinucleina, y usos de estos | |
| PE20250834A1 (es) | Composiciones y metodos para inhibir la expresion de mapt | |
| AR131419A1 (es) | TERAPÉUTICOS NOVEDOSOS DE iARN DE FAS Y USOS DE ESTOS | |
| AR123152A1 (es) | Composiciones y métodos para inhibir la expresión de plp1 | |
| AR128558A1 (es) | Oligonucleótido antisentido | |
| AR123160A1 (es) | Composiciones y métodos para inhibir la expresión de lpa |